**Using Medication Assisted Treatment in Treatment Courts – Personalized Medication (MAT)**

**Presenter: Percy Menzies**

Medication Assisted Treatment (MAT) is an evidence-based treatment that combines behavioral therapy and medications to treat substance use disorders. With the widening incidence of harmful heroin and other opiate use, it is more important than ever that treatment courts acknowledge and overcome all obstacles to the use of MAT in conjunction with psychosocial interventions for all participants assessed to need MAT. The NADCP board of directors issued a position statement in 2012 supporting the use of MAT, and the Adult Drug Court Best Practice Standards includes support for MAT as an adjunct to treatment. As of 2015, grant solicitations from SAMHSA and BJA have included language addressing the administration of MAT, along with funding availability for MAT. This session will outline the research on MAT, a brief description of the most common medications used in MAT.

**Learning Objectives-**At the end of this session, participants will be able to:

• Learn the basis for MAT use as an adjunct to treatment.

• Identify the medications most commonly used in MAT

• Learn the medications currently FDA-approved for the treatment of Opioid Use Disorders

• Learn the key indications and contradictions for medications used to treat Opioid Use Disorders

• Learn how physicians decide on treatment changes and reduce the risk of diversion

Using Compressed Timeframes from the Bench: Therapeutic Techniques for Treatment Court Judges, Attorneys and Coordinators

**Speaker: Percy Menzies**

Percy Menzies is the president of Assisted Recovery Centers of America, LLC, and an outpatient center for the treatment of alcoholism and drug addiction based in St. Louis, Missouri. The clinics treat more than 1000 patients a month through an integrated medical approach combining anticraving medications with behavioral therapies.

The ARCA clinics, established in 2001 have standardized the treatment of addictive disorders and developed strategies to reduce rates of recidivism by offering the bulk of the treatment in patient’s ‘home’ environment which is often filled with cues and triggers of past drug or alcohol.

Percy’s interest and passion for pharmacotherapy for the treatment of addictive disorders goes back to the early eighties when two non-opioids medications, naloxone (Narcan) and naltrexone were introduced for the treatment of opioid addiction. He worked for over 18 years for DuPont Pharmaceuticals, the company that developed these medications.

He has served on various state and federal committees to develop policies and guidelines for the treatment of opioid addiction and alcoholism. He has conducted workshops in the US and abroad on the advances in the treatment of addictive disorders.

Percy holds a master’s degree in pharmacy from India and immigrated to the United States in 1977.